Imipenem (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Imipenem" in English language version.

Last modified: 14:03:38, 17 April 2026 (UTC)

Ref.Un. Ref.Website

Global rank English rank

88nih.gov

5^th place

55doi.org

2^nd place

11patents.google.com

1,154^th place

606^th place

11semanticscholar.org

15^th place

8^th place

11books.google.com

3^rd place

11hdl.handle.net

66^th place

34^th place

11web.archive.org

1^st place

11toku-e.com

low place

books.google.com (Global: 3^rd place; English: 3^rd place)

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 497. ISBN 978-3-527-60749-5.

doi.org (Global: 2^nd place; English: 2^nd place)

Clissold SP, Todd PA, Campoli-Richards DM (March 1987). "Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy". Drugs. 33 (3): 183–241. doi:10.2165/00003495-198733030-00001. PMID 3552595. S2CID 209144637.
Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME (December 2012). "Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis". The Journal of Antimicrobial Chemotherapy. 67 (12): 2793–803. doi:10.1093/jac/dks301. PMID 22915465.
Kahan FM, Kropp H, Sundelof JG, Birnbaum J (December 1983). "Thienamycin: development of imipenen-cilastatin". The Journal of Antimicrobial Chemotherapy. 12 Suppl D: 1–35. doi:10.1093/jac/12.suppl_d.1. PMID 6365872.
Kesado T, Hashizume T, Asahi Y (June 1980). "Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics". Antimicrobial Agents and Chemotherapy. 17 (6): 912–7. doi:10.1128/aac.17.6.912. PMC 283902. PMID 6931548.
Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA (August 2014). "The risk of seizures among the carbapenems: a meta-analysis". The Journal of Antimicrobial Chemotherapy. 69 (8): 2043–55. doi:10.1093/jac/dku111. PMID 24744302.

hdl.handle.net (Global: 66^th place; English: 34^th place)

The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. Geneva: World Health Organization. 2025. hdl:10665/382243.

nih.gov (Global: 5^th place; English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Clissold SP, Todd PA, Campoli-Richards DM (March 1987). "Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy". Drugs. 33 (3): 183–241. doi:10.2165/00003495-198733030-00001. PMID 3552595. S2CID 209144637.
Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME (December 2012). "Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis". The Journal of Antimicrobial Chemotherapy. 67 (12): 2793–803. doi:10.1093/jac/dks301. PMID 22915465.
Kahan FM, Kropp H, Sundelof JG, Birnbaum J (December 1983). "Thienamycin: development of imipenen-cilastatin". The Journal of Antimicrobial Chemotherapy. 12 Suppl D: 1–35. doi:10.1093/jac/12.suppl_d.1. PMID 6365872.
Kesado T, Hashizume T, Asahi Y (June 1980). "Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics". Antimicrobial Agents and Chemotherapy. 17 (6): 912–7. doi:10.1128/aac.17.6.912. PMC 283902. PMID 6931548.
"Imipenem-Cilastatin". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 17 January 2017. PMID 31644018. NBK548708. Retrieved 19 March 2020. {{cite book}}: |website= ignored (help)
Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA (August 2014). "The risk of seizures among the carbapenems: a meta-analysis". The Journal of Antimicrobial Chemotherapy. 69 (8): 2043–55. doi:10.1093/jac/dku111. PMID 24744302.

ncbi.nlm.nih.gov

Kesado T, Hashizume T, Asahi Y (June 1980). "Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics". Antimicrobial Agents and Chemotherapy. 17 (6): 912–7. doi:10.1128/aac.17.6.912. PMC 283902. PMID 6931548.
"Imipenem-Cilastatin". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 17 January 2017. PMID 31644018. NBK548708. Retrieved 19 March 2020. {{cite book}}: |website= ignored (help)

patents.google.com (Global: 1,154^th place; English: 606^th place)

U.S. patent 4,194,047

semanticscholar.org (Global: 15^th place; English: 8^th place)

api.semanticscholar.org

Clissold SP, Todd PA, Campoli-Richards DM (March 1987). "Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy". Drugs. 33 (3): 183–241. doi:10.2165/00003495-198733030-00001. PMID 3552595. S2CID 209144637.

toku-e.com (Global: low place; English: low place)

"Imipenem spectrum of bacterial susceptibility and Resistance" (PDF). Archived from the original (PDF) on 3 March 2016. Retrieved 4 May 2012.

web.archive.org (Global: 1^st place; English: 1^st place)

"Imipenem spectrum of bacterial susceptibility and Resistance" (PDF). Archived from the original (PDF) on 3 March 2016. Retrieved 4 May 2012.

Imipenem (English Wikipedia)

books.google.com (Global: 3rd place; English: 3rd place)

doi.org (Global: 2nd place; English: 2nd place)

hdl.handle.net (Global: 66th place; English: 34th place)

nih.gov (Global: 5th place; English: 5th place)